Welcome to our dedicated page for Lipocine news (Ticker: LPCN), a resource for investors and traders seeking the latest updates and insights on Lipocine stock.
Lipocine Inc. (LPCN) is a clinical-stage biopharmaceutical innovator advancing oral therapies for endocrine and central nervous system disorders. This page serves as the definitive source for verified news and press releases related to Lipocine's product pipeline, clinical trials, and strategic developments.
Investors and industry professionals will find timely updates on key initiatives including progress in postpartum depression treatments (LPCN 1154), testosterone replacement therapy (TLANDO), and novel therapies for liver cirrhosis. Our curated news collection provides:
• Clinical trial milestones
• Regulatory updates
• Partnership announcements
• Scientific publications
All content is sourced directly from company filings and authorized communications, ensuring reliability for investment research. Bookmark this page for streamlined access to Lipocine's latest advancements in oral drug delivery technology and therapeutic development.
Lipocine Inc. (NASDAQ: LPCN) announced the dosing of the first participant in a pilot clinical bridge study of LPCN 1154, an oral formulation of brexanolone aimed at treating postpartum depression (PPD). The FDA supports Lipocine's proposal to validate LPCN 1154's efficacy through a pharmacokinetic bridge to intravenous brexanolone. The pilot study, involving 12 participants, seeks to compare the safety and tolerability of LPCN 1154 with the approved injectable form. Results are anticipated in the first half of 2023, with the potential for a pivotal study and NDA filing based on these findings.
Lipocine Inc. (NASDAQ: LPCN) announced its financial results for the year ended December 31, 2022, highlighting a strategic shift towards developing neuroactive steroids for CNS disorders. The company reported a net loss of $10.8 million, or ($0.13) per diluted share, compared to a loss of $634,399, or ($0.01) per diluted share in 2021. License revenue significantly declined to $500,000 from $16.1 million in 2021. Research and development expenses rose to $8.6 million, driven by increased clinical study costs. As of December 31, 2022, the company had $32.5 million in cash, down from $46.6 million in 2021.
FAQ
What is the current stock price of Lipocine (LPCN)?
What is the market cap of Lipocine (LPCN)?
